Literature DB >> 18539889

Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.

Yoshiharu Ohno1, Hisanobu Koyama, Yumiko Onishi, Daisuke Takenaka, Munenobu Nogami, Takeshi Yoshikawa, Sumiaki Matsumoto, Yoshikazu Kotani, Kazuro Sugimura.   

Abstract

PURPOSE: To prospectively and directly compare the capability of whole-body diffusion-weighted (DW) imaging, whole-body magnetic resonance (MR) imaging with and that without DW imaging, and integrated fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) for M-stage assessment in non-small cell lung cancer (NSCLC) patients.
MATERIALS AND METHODS: The institutional review board approved this study; informed consent was obtained from patients. A total of 203 NSCLC patients (109 men, 94 women; mean age, 72 years) prospectively underwent whole-body DW imaging, whole-body MR imaging, and FDG PET/CT. Final diagnosis of the M-stage in each patient was determined on the basis of results of all radiologic and follow-up examinations. Two chest radiologists and two nuclear medicine physicians independently assessed all examination results and used a five-point visual scoring system to evaluate the probability of metastases. Final diagnosis based on each of the methods was made by consensus of two readers. Receiver operating characteristic (ROC) analysis was used to compare the capability for M-stage assessment among whole-body DW imaging, whole-body MR imaging with and that without DW imaging, and PET/CT on a per-patient basis. Sensitivity, specificity, and accuracy were compared with the McNemar test.
RESULTS: Area under ROC curve (A(z)) values of whole-body MR imaging with DW imaging (A(z) = 0.87, P = .04) and integrated FDG PET/CT (A(z) = 0.89, P = .02) were significantly larger than that of whole-body DW imaging (A(z) = 0.79). Specificity and accuracy of whole-body MR imaging with (specificity, P = .02; accuracy, P < .01) and that without DW imaging (specificity, P = .02; accuracy, P = .01) and integrated FDG PET/CT (specificity, P < .01; accuracy, P < .01) were significantly higher than those of whole-body DW imaging.
CONCLUSION: Whole-body MR imaging with DW imaging can be used for M-stage assessment in NSCLC patients with accuracy as good as that of PET/CT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18539889     DOI: 10.1148/radiol.2482072039

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  77 in total

Review 1.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

2.  Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.

Authors:  Gregor Sommer; Mark Wiese; Leopold Winter; Claudia Lenz; Markus Klarhöfer; Flavio Forrer; Didier Lardinois; Jens Bremerich
Journal:  Eur Radiol       Date:  2012-07-09       Impact factor: 5.315

Review 3.  Multiplexed imaging in cancer diagnosis: applications and future advances.

Authors:  Hisataka Kobayashi; Michelle R Longmire; Mikako Ogawa; Peter L Choyke; Satomi Kawamoto
Journal:  Lancet Oncol       Date:  2010-03-24       Impact factor: 41.316

4.  Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Authors:  Joshua H Finkle; Stephanie Y Jo; Mark K Ferguson; Hai-Yan Liu; Chenpeng Zhang; Xuee Zhu; Cindy Yuan; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-07       Impact factor: 9.236

5.  Computed diffusion-weighted imaging using 3-T magnetic resonance imaging for prostate cancer diagnosis.

Authors:  Yoshiko Ueno; Satoru Takahashi; Kazuhiro Kitajima; Tokunori Kimura; Ikuo Aoki; Fumi Kawakami; Hideaki Miyake; Yoshiharu Ohno; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2013-07-25       Impact factor: 5.315

6.  Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Authors:  Michael A Jacobs; Katarzyna J Macura; Atif Zaheer; Emmanuel S Antonarakis; Vered Stearns; Antonio C Wolff; Thorsten Feiweier; Ihab R Kamel; Richard L Wahl; Li Pan
Journal:  Acad Radiol       Date:  2018-04-04       Impact factor: 3.173

7.  Diffusion-weighted imaging can correctly identify false-positive lymph nodes on positron emission tomography in non-small cell lung cancer.

Authors:  Hiroaki Nomori; Yue Cong; Hiroshi Sugimura; Yoshiaki Kato
Journal:  Surg Today       Date:  2015-12-10       Impact factor: 2.549

Review 8.  Medical imaging in the diagnosis and management of cancer pain.

Authors:  Carlos Cuevas; Dean Shibata
Journal:  Curr Pain Headache Rep       Date:  2009-08

Review 9.  Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer.

Authors:  Michael A Jacobs; Li Pan; Katarzyna J Macura
Journal:  Semin Roentgenol       Date:  2009-04       Impact factor: 0.800

Review 10.  Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer.

Authors:  Michael A Jacobs; Ronald Ouwerkerk; Kyle Petrowski; Katarzyna J Macura
Journal:  Top Magn Reson Imaging       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.